WO2002016360A2 - Nitrogenous heterocyclic compounds - Google Patents

Nitrogenous heterocyclic compounds Download PDF

Info

Publication number
WO2002016360A2
WO2002016360A2 PCT/US2001/041749 US0141749W WO0216360A2 WO 2002016360 A2 WO2002016360 A2 WO 2002016360A2 US 0141749 W US0141749 W US 0141749W WO 0216360 A2 WO0216360 A2 WO 0216360A2
Authority
WO
WIPO (PCT)
Prior art keywords
quinazolin
methoxyethoxy
piperazinyl
pharmaceutically acceptable
carboxamide
Prior art date
Application number
PCT/US2001/041749
Other languages
French (fr)
Other versions
WO2002016360A3 (en
Inventor
Anjali Pandey
Robert M. Scarborough
Kenji Matsuno
Michio Ichimura
Yuji Nomoto
Shigeki Fujiwara
Shinichi Ide
Eiji Tsukuda
Junko Irie
Shoji Oda
Original Assignee
Cor Therapeutics, Inc.
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics, Inc., Kyowa Hakko Kogyo Co., Ltd. filed Critical Cor Therapeutics, Inc.
Priority to US10/344,907 priority Critical patent/US20040259881A1/en
Priority to AU2001293207A priority patent/AU2001293207A1/en
Priority to EP01973652A priority patent/EP1309567A2/en
Publication of WO2002016360A2 publication Critical patent/WO2002016360A2/en
Publication of WO2002016360A3 publication Critical patent/WO2002016360A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases.
  • the invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases.
  • PDGF platelet-derived growth factor
  • N,N-dimethyl- 4-(6,7-dimethoxy-4-quinazolinyl)-l-piperazine carboxamide is described as a bronchodilator in South African Patent No. 67 06512 (1968).
  • Dimethoxyquinazoline derivatives are described as inhibitors of phosphorylation of epidermal growth factor (EGF) receptor in Japanese Published Unexamined Patent Application No. 208911/93 and WO 96/09294.
  • Inhibitors of phosphorylation of PDGF receptor so far known include bismono- and bicyclic aryl compounds and heteroaryl compounds (WO 92/20642), quinoxaline derivatives [Cancer Research, 54, 6106 (1994)], pyrimidine derivatives (Japanese Published Unexamined Patent Application No. 87834/94) and dimethoxyquinoline derivatives [Abstracts of the 16th Annual Meeting of the Pharmaceutical Society of Japan (Kanazawa) (1996), 2, p. 275, 29(C2) 15-2].
  • An object of the present invention is to provide nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of the kinases.
  • Particularly important kinase inhibition according to the invention is of receptor tyrosine kinases including platelet-derived growth factor (PDGF) receptor, Flt3, CSF-IR, epidermal growth factor receptor (EGRF), fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGFR) and others.
  • Another class of kinase inhibition according to the invention is inhibitory activity nonreceptor tyrosine kinases including src and abl, and the like.
  • a third class of kinase inhibition according to the invention is inhibitory activity toward serine/threonine kinases, including such kinases as MAPK, MEK and cyclin dependent kinases (CDKs) that mediate cell prolifetation, AKT and CDK such that mediate cell survival and NTK that regulate inflammatory responses.
  • kinases as MAPK, MEK and cyclin dependent kinases (CDKs) that mediate cell prolifetation, AKT and CDK such that mediate cell survival and NTK that regulate inflammatory responses.
  • Inhibition of such kinases can be used to treat diseases involving cell survival, proliferation and migration, including cardiovascular disease, such as arteriosclerosis and vascular reobstruction, cancer, glomerulosclerosis fibrotic diseases and inflammation, as well as the general treatment of cell-proliferative diseases.
  • the present invention provides compounds and pharmaceutically acceptable salts thereof which inhibit or prevent inhibition of phosphorylation of at least one PDGF receptor by at least one tyrosine kinase.
  • PDGF receptor kinase inhibition can hinder abnormal cell growth and cell wandering, and thus such compounds are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
  • the present invention relates to nitrogen-containing heterocyclic compounds represented by formula I as follows:
  • X is O or S
  • Ris a member selected from the group consisting of:
  • R 1 and R 2 are each independently a member selected from the group consisting of -OH,
  • the invention provides such compounds wherein n and m are each independently 2 or 3.
  • the pharmaceutically acceptable salts of the compounds according to formula (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, etc.
  • pharmaceutically acceptable acid addition salts of the compounds of formula (I) are inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, tartrate, citrate and methanesulfonate.
  • Examples of the pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt.
  • Examples of the pharmaceutically acceptable ammonium salts are ammonium salt and tetramethyl ammonium salt.
  • Examples of the pharmaceutically acceptable organic amine addition salts include heterocyclic amine salts such as morpholine and piperidine salts.
  • Examples of the pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine and phenylalanine.
  • R is defined as described above for formula I,
  • the invention provides compounds according to formula 1(b) as follows:
  • R, R 2 and m are each independently defined as described above for formula I,
  • R, R 1 and n are each independently defined as described above for formula I,
  • an especially preferred embodiment of the present invention is a compound selected from the group consisting of:
  • the compounds may be prepared using methods and procedures as generally described in WO 98/14431 published September 12, 1998, which is incorporated herein by reference. Starting materials may be made or obtained as described therein as well. Leaving groups such as halogen, lower alkoxy, lower alkylthio, lower alkylenesulfonyloxy, arylsulfonyloxy, etc, may be utilized when necessary except for the reaction point, followed by deprotection. Suitable amino protective groups are, for example, those described in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981), etc., such as ethoxycarbonyl, t-butoxycarbonyl, acetyl and benzyl.
  • the protective groups can be introduced and eliminated according to conventional methods used in organic synthetic chemistry [e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981)]. In such processes, if the defined groups change under the conditions of the working method or are not appropriate for carrying out the method, the desired compound can be obtained by using the methods for introducing and eliminating protective groups which are conventionally used in organic synthetic chemistry [e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981)], etc. Conversion of functional groups contained in the substituents can be carried out by known methods [e.g., R. C. Larock, Comprehensive Organic Transformations (1989)] in addition to the above-described processes, and some of the active compounds of formula I may be utilized as intermediates for further synthesizing novel derivatives according to formula I.
  • the intermediates and the desired compounds in the processes described above can be isolated and purified by purification methods conventionally used in organic synthetic chemistry, for example, neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography.
  • the intermediates may be subjected to the subsequent reaction without purification.
  • a salt of a compound of formula I is desired and the compound is produced in the form of the desired salt, it can be subjected to purification as such.
  • the compound of formula I is dissolved or suspended in a suitable organic solvent, followed by addition of an acid or a base to form a salt.
  • the synthesis of 4-Cl-quinazoline is effected by treating 4-quinazolinone with halogenatmg reagents such as thionyl chloride, oxalyl chloride or phosphorous oxychloride in presence of solvent such as toluene, or carbon tetrachloride.
  • halogenatmg reagents such as thionyl chloride, oxalyl chloride or phosphorous oxychloride in presence of solvent such as toluene, or carbon tetrachloride.
  • the key intermediate is obtained by treating 4-C1- quinazoline with piperazine in an appropriate solvent, such as isopropanol, acetonitrile, or THF at room or reflux temperature for l-6h in presence of base triethylamine or pyridine.
  • Scheme 2 (below) provides the synthesis of various substituted urea intermediates from the intermediate obtained above in Scheme 1, or by other procedures.
  • the piperazine intermediate may be treated with phosgene to give a carbamoyl chloride intermediate followed by reaction with various substituted anilines.
  • the piperazine intermediate can also be treated with p-nitrophenyl chloroformate to afford a nitrophenyl carbamate intermediate that can be treated with various anilines to afford the desired ureas.
  • the urea compound has a terminal NH 2 group (or one or more of the hydrogen atoms on this amino group is replaced by a displaceable substituent), then this compound may be utilized an intermediate compound with which to produce a urea compound terminated with a -NH-phenyl-R 1 groups.
  • a replaceable para position leaving group phenyl substituent may be displaced after coupling to provide the particular R 1 substituent as described for formula I, above.
  • the compounds of formula I and pharmaceutically acceptable salts thereof may exist in the form of adducts with water (hydrates) or various solvents, which are also within the scope of the present invention.
  • Example 1 The following non-limiting examples are provided to better illustrate the present invention.
  • Example 1 The following non-limiting examples are provided to better illustrate the present invention.
  • Step A To the acetone solution (lOmL) of ethyl 3,4-dihydroxybenzoate (0.910g, 5mmol), K 2 CO 3 (1.52g, llmmol), nBu 4 NI (20mg) was added 2-bromoethylmethyl ether (1.17mL, 12.5mmol). The mixture was stirred overnight at 100°C under argon. After cooling, to this added ether and the precipitate was filtered, the filtrate was evaporated to afford the desired product as white solid (0.850g, 60%).
  • Step B To the acetic acid (4mL) solution of ethyl-3,4-bis(2-methoxyethoxy)benzoate (0.710g, 2.4mmol) at -10°C was slowly added nitric acid ( 0.350mL). After stirring at this temperature for lh, added KNO 3 (0.240g, 2.4mmol) and H 2 SO 4 (0.180mL) followed by stirring at room temperature overnight. The reaction was poured in ice and extracted with EtOAc, washed with brine, dried, filtered and evaporated to give brown oil (0.800g, quantitative). MS(ES) 344 (M+H) +
  • Step C To the EtOH (lOmL) solution of nitro material from Step B (0.686g, 2mmol) added PtO 2 (40mg, 0.16mmol) and then the mixture was shaken on Parr hydrogenation apparatus at 45psi of H 2 for overnight. Filtration of the catalyst through celite and evaporation of the solvent under vacuum gave the desired amino ester (0.600g).
  • Step D The amino product (lg, 3.21mmol) from Step C was dissolved in formamide (4mL) to this added ammonium formate (0.298g, 4.71mmol) and the reaction mixture was heated at 150°C for 4h. After cooling to room temperature, the solution was diluted with water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, filtered and evaporated to give beige-colored solid (0.600g, 62%).
  • Step E A mixture of 6,7-bis(2-methoxyethoxy)-4-quinazolinone (0.969g, 3.3mmol) and POCl 3 (4.5mL) was heated to reflux under argon for 6h. After cooling to 0°C, added dropwise cone. NH 4 OH, a solid precipitated which was collected by filtration. The solid collected was washed with water and dried under high vacuum to afford desired 4- chloroquinazoline.
  • Step F To the isopropanol solution (5mL) of 6,7-bis(2-methoxyethoxy)-4-Cl-quinazoline (0.156g, 0.5mmol, from Step E) added piperazine (0.300g, 3.5mmol) and the reaction mixture was refluxed for 3h. The solvent was evaporated and the residue dissolved in EtOAc and washed with brine, dried, filtered and evaporated to give desired key intermediate 6,7-bis(2-methoxyethoxy)-4-piperazinyquinazoline as a white solid (0.150g). MS(ES) 363(M+H)
  • Step A To the anhydrous DMSO solution (7mL) of phenol (0.44g, 4.7mmol) added NaH (0.24g, 6.05mmol) and stirred for 45min at room temperature. To this added l-fluoro-4- nitrobenzene(0.66g, 4.65mmol) and this was heated at 90°C for overnight. After cooling diluted with EtOAc and washed with brine, dried, filtered, evaporated to afford crude residue. This was purified by silica gel cliromatography (10%EtOAc/hexane) to give desired product as bright yellow oil (0.91 g, 91%). MS(ES) 216 (M+H)
  • Step B The nitro compound from Step A (0.885g, 4.12mmol) was dissolved in
  • Step A To the DMF solution (12mL) of Ethyl-3-hydroxy-4-fluorobenzoate (0.80g, 4.35mmol) added K 2 CO 3 (2.10g, 15.22mmol) followed by 2-bromoethyl methylether
  • Step B To a DMF solution (lOmL) of 2-piperidineethanol (2.86mL, 21.6mmol) added NaH(0.83g, 20.9mmol) at 0°C and the mixture was stirred for lh. To this added DMF solution (3mL) of ester (0.725g, 3.15mmol, from Step A, Example 4) and heated the reaction at 90°C overnight. The solvent was evaporated and the residue purified by RP-HPLC to afford the desired ethyl 3-(2-methoxyethoxy)-4-(2-piperidylethoxy)benzoate as a off-white solid. MS(ES) 352(M+H)
  • Step C To the acetic acid (3mL) solution of ethyl 3-(2-methoxyethoxy)-4- (2- piperidylethoxy)benzoate (0.197g, 0.56mrno ⁇ ) at -10°C was slowly added nitric acid ( 0.200mL). After stirring at this temperature for lh, added KNO 3 (0.056g, 0.56mmol) and H 2 SO 4 (0.200mL) slowly warmed up to room temperature and stirred for lh. The reaction was poured in ice, basified with NH4OH, and extracted with EtOAc. The EtOAc layer was separated, dried, filtered and evaporated to give white solid (0.200g, 95%).
  • Step E The amino product (0.160g, 0.437mmol) from Step D was dissolved in formamide (0.278mL, 7mmol)) to this added ammonium formate (0.256g, 4.36mmol) and the reaction mixture was heated at 135°C for 4h. After cooling to room temperature, the solution was diluted with water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, filtered and evaporated to give off-white solid (0.198g, 96%). MS(ES) 370 (M+Na).
  • Step F To 4-quinazolinone (0.195g, 0.423mmol, From Step E) added SOCl 2 (3mL), DMF (0.200mL) and the mixture was heated at 90°C for lh. After cooling evaporated the solvent and azetroped several times with toluene to afford the desired 4-Cl-quinazoline as tan crystalline solid (0.197g).
  • ES(MS) 366 (M+H, with 1C1).
  • Step G To the isopropanol solution (8mL) of the material from Step F (0.190g, 0.423mmol) added Boc-piperazine (0.197g, 1.06mmol) followed by Et 3 N (0.288mL, 2.1 lmmol). The reaction mixture was heated to reflux overnight. The solvent was evaporated and the residue purified by RP-HPLC to afford desired product tert-butyl-4-[6- (2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl]piperazinylcarboxylate (0.173g, 62%). MS(ES) 516 (M+H).
  • the pharmacological activities of the compounds of the present invention are obtained by following the test example procedures as follows, for example.
  • the HR5 cell line is a cell line of CHO cells engineered to overexpress human ?-PDGFR, which cell line is available from the ATCC.
  • the expression level of /?-PDGFR in HR5 cells is around 5 xlO 4 receptor per cell.
  • HR5 cells were grown to confluency in 96-well microtiter plates under standard tissue culture conditions, followed by serum-starvation for 16 hours. Quiescent cells were incubated at 37°C without or with increasing concentrations of the test compound (0.01-30 ⁇ M) for 30 minutes followed by the addition of 8 nM PDGF BB for 10 minutes.
  • Cells were lysed in 100 mM Tris, ⁇ H7.5, 750 mM NaCl, 0.5% Triton X-100, 10 mM sodium pyrophosphate, 50 mM NaF, 10 ug/ml aprotinin, 10 ug/ml leupeptin, lmM phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, and the lysate was cleared by centrifugation at 15,000 x g for 5 minutes.
  • Clarified lysates were transferred into a second microtiter plate in which the wells were previously coated with 500 ng/well of 1B5B11 anti- ⁇ -PDGFR mAb, and then incubated for two hours at room temperature. After washing three times with binding buffer (0.3% gelatin, 25mM Hepes pH 7.5, lOOmM NaCl, 0.01% Tween-20), 250 ng/ml of rabbit polyclonal anti-phosphotyrosine antibody (Transduction Laboratory) was added and plates were mcubated at 37°C for 60 minutes.
  • binding buffer 0.3% gelatin, 25mM Hepes pH 7.5, lOOmM NaCl, 0.01% Tween-20
  • IC 50 expressed as the concentration of a compound according to the invention that inhibits the PDGF receptor phosphorylation by 50% as compared to control cells that are not exposed to a compound according to the invention.
  • the MG63 cell line is a human osteosarcoma tumor cell line available from the
  • This assay is for measuring endogenous 7-PDGFR phosphorylation in MG63 cells.
  • the assay conditions are the same as those described for HR5 cell, except that PDGF-BB stimulation is provided in the presence or absence of 45% human plasma.
  • the MG63 assay results are reported as an IC 50 (expressed as the concentration of a compound according to the invention that inhibits the PDGF receptor phosphorylation by 50%) as compared to control cells that are not exposed to a compound according to the invention. Examples of such IC 50 test results in the MG63 assay for compounds according to the invention are set forth below in Table 1.
  • Vascular smooth muscle cells are isolated from a pig aorta by explanation and used for the test. The cells are put into wells of a 96-well plate (8000 cells/well) and cultured in
  • DMEM Dulbeccois modified Eagle's medium
  • FBS fetal bovine serum
  • DMEM containing 0.1 % FBS for 3 days are synchronized at the cell growth stationary phase.
  • the test result is expressed as the concentration of a test compound which inhibits the cell growth by 50% (IC 50 ).
  • a test compound is suspended in a 0.5% solution of Tween 80 in an aqueous solution of sodium chloride to a concentration of 20 mg/ml in the case of intraperitoneal administration and in a 0.5% solution of methyl cellulose 400 to a concentration of 6 mg/ml in the case of oral administration.
  • the suspension is administered once a day in the case of intraperitoneal administration and once or twice a day in the case of oral administration for a period of 15 days starting on the day before the balloon injury.
  • the animal On the 14th day after the balloon injury, the animal is killed and its left carotid is extirpated.
  • the tissues are fixed with formalin, wrapped in paraffin and sliced, followed by Elastica Wangeeson staining.
  • the area of the cross section of the vascular tissues is measured with an image analyzer
  • Dead cells of Mycobacterium bacterium are disrupted in agate mortar and suspended in liquid paraffin to the final concentration of 6.6 mg/ml, followed by sterilization with high pressure steam. Then, 100 ml of the suspension is subcutaneously injected into the right hind foot pad of each animal of groups of female 8-weeks-old Lewis rats (Charles River Japan) (6 animals/group) to induce adjuvant arthritis.
  • a test compound i suspended in a 0.5 % solution of methyl cellulose to the final concentration of 3 mg/ml, and from just before the induction of arthritis, the suspension is orally administered in an amount of 100 ml/100 g of the body weight once a day, 5 days a week.
  • a control group is administered a 0.5% solution of methyl cellulose.
  • a normal group is given no adjuvant treatment or test compound administration.
  • the administration of the test compound is continued till the 18th day after the adjuvant treatment.
  • the number of leukocytes in peripheral blood are counted, and on the 18th day, all the blood is collected, followed by dissection.
  • the change in body weight with the passage of time, the change of edema in hind foot with the passage of time, the weight of spleen and thymus, the number of leukocytes in peripheral blood, the hydroxyproline content of urine, the glucosaminoglycan content of urine, the SH concentration in serum, the concentration of nitrogen monoxide in serum and the concentration of mucoprotein in serum are measured and evaluated.
  • the volume of each of both hind feet are measured using a rat's hind foot edema measurement device (TK-101, Unicom).
  • the number of leukocytes in peripheral blood are counted using an automatic multichannel blood cell counter (Sysmex K-2000, Toa Iyo Denshi Co., Ltd.).
  • the hydroxyproline content of urine is measured according to the method described in Ikeda, et al., Annual Report of Tokyo Metropolitan Research Laboratories P. H., , 36, 277 (1985), and the glucosaminoglycan content is measured according to the method described in Moriyama, et al., Hinyo Kiyo, 40, 565 (1994) and Klompmakers, et al., Analytical Biochemistry, 153, 80 (1986).
  • the SH concentration in serum is measured according to the method described in Miesel, et al, inflammation, 17, 595 (1993), and the concentration of nitrogen monoxide is measured according to the method ofTracey, et al., Journal of Pharmacology & Experimental Therapeutics, 272, 1011 (1995).
  • the concentration of mucoprotein is measured using Aspro GP Kit (Otsuka Pharmaceutical Co., Ltd.). The percentage inhibition for each indication is calculated according to the following equation.
  • % Inhibition ⁇ (Control group - Compound-administered group)/(Control group - Normal group) ⁇ x 100.
  • Anti-rat Thy-1.1 monoclonal antibody OX-7 (Sedaren) is administered to male Wister-Kyoto rats (Charles River Japan, 160 g, 6 animals/group) in an amount of 1.0 mg/kg by intravenous administration through the tail vein.
  • a test compound is suspended in a 0.5% solution of methylcellulose and the resulting suspension is administered to each of the rats twice a day for a period of 7 days starting on the day before the administration of OX-7.
  • On the 7th day after the OX-7 administration when mesangial cell growth and extracellular matrix hypertrophy become prominent, the left kidney of each rat is extirpated, fixed with 20% buffered formalin for 6 hours and wrapped in paraffin, followed by slicing.
  • the obtained pieces are subjected to immune tissue staining using antibody PC 10 (DAKO) against an intranuclear antigen of proliferative cells.
  • DAKO antibody PC 10
  • Methyl Green staining solution using diaminobenzidine as a color developer
  • the paraffin pieces are enclosed.
  • Half of the glomeruli in a kidney piece are observed and the number of the cells in one glomerulus which are positive to the intranuclear antigen of proliferative cells are calculated.
  • the test for the significance of difference is carried out by the Wilcoxon test.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be administered as such, but it is usually preferred to administer them in the form of pharmaceutical compositions, which are used for animals and human beings. It is preferred to employ the administration route which is the most effective for the treatment. For example, administration is made orally or non-orally by intrarectal, intraoral, subcutaneous, intramuscular or intravenous administration.
  • Examples of the forms for administration are capsules, tablets, granules, powders, syrups, emulsions, suppositories and injections.
  • Liquid compositions such as emulsions and syrups which are appropriate for oral administration can be prepared using water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as benzoates, flavors such as strawberry flavor and peppermint, etc.
  • Capsules, tablets, powders and granules can be prepared using excipients such as lactose, glucose, sucrose and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, etc.
  • excipients such as lactose, glucose, sucrose and mannitol
  • disintegrating agents such as starch and sodium alginate
  • lubricants such as magnesium stearate and talc
  • binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin
  • surfactants such as fatty acid esters
  • plasticizers such as glycerin, etc.
  • compositions suitable for non-oral administration preferably comprise a sterilized aqueous preparation containing an active compound which is isotonic to the recipient's blood.
  • injections are prepared using a carrier which comprises a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
  • compositions for topical application are prepared by dissolving or suspending an active compound in one or more kinds of solvents such as mineral oil, petroleum and polyhydric alcohol, or other bases used for topical drugs.
  • Compositions for intestinal administration are prepared using ordinary carriers such as cacao fat, hydrogenated fat and hydrogenated fat carboxylic acid, and are provided as suppositories.
  • compositions for non-oral administration may additionally be formulated to contain one or more kinds of additives selected from glycols, oils, flavors, preservatives
  • compositions for oral administration which are used for the preparation of compositions for oral administration.
  • the effective dose and the administration schedule for each of the compounds of formula (I) or a pharmaceutically acceptable salt thereof will vary depending on the administration route, the patient's age and body weight, and the type or degree of the diseases to be treated. However, it is generally appropriate to administer a compound of formula (I) or a pharmaceutically acceptable salt thereof in a dose of 0.01-1000 mg/adult/day, preferably 5-500 mg/adult/day, in one to several parts.
  • All the compounds of the present invention can be immediately applied to the treatment of kinase-dependent diseases of mammals as kinase inhibitors, specifically, those relating to tyrosine kinase.
  • kinase inhibitors specifically, those relating to tyrosine kinase.
  • the compounds which have IC50 within the range of 10 nM-10 ⁇ M Even more preferred are compounds which have IC50 within the range of 10 ⁇ M to -1 ⁇ M.
  • Most preferred are compounds which have an IC50 value which is smaller than 1 ⁇ M.
  • Tyrosine kinase-dependent diseases include hyperproliferative malfunction which is caused or maintained by abnormal tyrosine kinase activity. Examples thereof include psoriasis, pulmonary fibrosis, glomerulonephritis, cancer, atherosclerosis and anti-angiopoiesis (for example, tumor growth and diabetic retinopathy).
  • the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Description

NITROGENOUS HETEROCYCLIC COMPOUNDS
Technical Field
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases.
Background Art PDGF (platelet-derived growth factor) is known to act as an aggravating factor for cell-proliferative diseases such as arteriosclerosis, vascular reobstruction after percutaneous coronary angioplasty and bypass operation, cancer, glomerulonephritis, glomerulosclerosis, psoriasis and articular rheumatism [Cell, 46, 155-169 (1986); Science, 253, 1129-1132 (1991); Nippon Rinsho (Japanese J. of Clinical Medicine), 50, 3038-3045 (1992); Nephrol Dial Transplant, 10, 787-795 (1995); Kidney International, 43 (Suppl. 39), 86-89 (1993); Journal of Rheumatology, 21, 1507-1511 (1994); Scandinavian Journal of hnmunology, 27, 285-294 (1988), etc.].
As for quinazoline derivatives which are useful as drugs, N,N-dimethyl- 4-(6,7-dimethoxy-4-quinazolinyl)-l-piperazine carboxamide is described as a bronchodilator in South African Patent No. 67 06512 (1968). Dimethoxyquinazoline derivatives are described as inhibitors of phosphorylation of epidermal growth factor (EGF) receptor in Japanese Published Unexamined Patent Application No. 208911/93 and WO 96/09294. Quinoline derivatives having benzodiazepin receptor agonist activity are described in Pharmacology Biochemistry and Behavior, 53, 87-97 (1996) and European Journal of Medicinal Chemistry, 31, 417-425 (1996), and quinoline derivatives which are useful as anti-parasite agents are described in Indian Journal of Chemistry, 26B, 550-555 (1987).
Inhibitors of phosphorylation of PDGF receptor so far known include bismono- and bicyclic aryl compounds and heteroaryl compounds (WO 92/20642), quinoxaline derivatives [Cancer Research, 54, 6106 (1994)], pyrimidine derivatives (Japanese Published Unexamined Patent Application No. 87834/94) and dimethoxyquinoline derivatives [Abstracts of the 16th Annual Meeting of the Pharmaceutical Society of Japan (Kanazawa) (1996), 2, p. 275, 29(C2) 15-2].
Disclosure of the Invention
An object of the present invention is to provide nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of the kinases. Particularly important kinase inhibition according to the invention is of receptor tyrosine kinases including platelet-derived growth factor (PDGF) receptor, Flt3, CSF-IR, epidermal growth factor receptor (EGRF), fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGFR) and others. Another class of kinase inhibition according to the invention is inhibitory activity nonreceptor tyrosine kinases including src and abl, and the like. A third class of kinase inhibition according to the invention is inhibitory activity toward serine/threonine kinases, including such kinases as MAPK, MEK and cyclin dependent kinases (CDKs) that mediate cell prolifetation, AKT and CDK such that mediate cell survival and NTK that regulate inflammatory responses. Inhibition of such kinases can be used to treat diseases involving cell survival, proliferation and migration, including cardiovascular disease, such as arteriosclerosis and vascular reobstruction, cancer, glomerulosclerosis fibrotic diseases and inflammation, as well as the general treatment of cell-proliferative diseases.
In a preferred embodiment, the present invention provides compounds and pharmaceutically acceptable salts thereof which inhibit or prevent inhibition of phosphorylation of at least one PDGF receptor by at least one tyrosine kinase. Such PDGF receptor kinase inhibition can hinder abnormal cell growth and cell wandering, and thus such compounds are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The present invention relates to nitrogen-containing heterocyclic compounds represented by formula I as follows:
Figure imgf000004_0001
wherein m and n are each independently from 2 to 8,
X is O or S; and
Ris a member selected from the group consisting of:
-CN, -C-(CH3)33 -C-(CF3)2-OH, -N(-Cw alkyl)2, -O-CH(CH3)2,
Figure imgf000004_0002
R1 and R2 are each independently a member selected from the group consisting of -OH,
-O-CH3 and
Figure imgf000005_0001
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
In a preferred aspect, the invention provides such compounds wherein n and m are each independently 2 or 3.
The pharmaceutically acceptable salts of the compounds according to formula (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, etc. Examples of the pharmaceutically acceptable acid addition salts of the compounds of formula (I) are inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, tartrate, citrate and methanesulfonate. Examples of the pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt. Examples of the pharmaceutically acceptable ammonium salts are ammonium salt and tetramethyl ammonium salt. Examples of the pharmaceutically acceptable organic amine addition salts include heterocyclic amine salts such as morpholine and piperidine salts. Examples of the pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine and phenylalanine.
hi a preferred embodiment the invention provides compounds according to formula 1(a) as follows:
Figure imgf000006_0001
wherein
R is defined as described above for formula I,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
In another preferred embodiment the invention provides compounds according to formula 1(b) as follows:
Figure imgf000006_0002
wherein R, R2 and m are each independently defined as described above for formula I,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof. In another preferred embodiment the invention provides compounds according to formula 1(c) as follows:
Figure imgf000007_0001
wherein
R, R1 and n are each independently defined as described above for formula I,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
Further, an especially preferred embodiment of the present invention is a compound selected from the group consisting of:
Figure imgf000008_0001
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-naphthyloxyphenyl) carboxam ide
Figure imgf000008_0002
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-(5-isoquinolyloxy)phenyl) carboxam ide
Figure imgf000008_0003
{4-[6,7-bis(2-m ethoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-indol-4-yloxyphenyl) carboxamide
Figure imgf000008_0004
{4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl]piperazinyl}- N-(4-phenoxyp enyl)carboxamide
Figure imgf000009_0001
N-(4-cyanophenyl){4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl] piperazinyljcarboxamide
Figure imgf000009_0002
{4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazoIin-4-yl]piperazinyl}- N-[4-( ethylethoxy)phenyl]carboxamide
Figure imgf000009_0003
N-(4-cyanophenyl){4-[6-(2-methoxyethoxy)-7-(2-morpholin-4-ylethoxy)quinazolin-4-yl] piperazinyljcarboxam ide
O_^N— <\ Λ— CN
N
X.
o {4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-[4-(3-chIoro-4-methylphenoxy) phenyljcarboxamide
Figure imgf000010_0001
{4-t6J-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-[4-(4-bromophenoxy)phenyl] carboxamide
Figure imgf000010_0002
{4-[6J-bis(2-methoxyet oxy)quinazolin-4-yl]piperazinyl}-N-(4-cyclopropylp enyl) carboxamide
Figure imgf000010_0003
Figure imgf000010_0004
{4-[6,7-bis(2-methoxyet oxy)quinazolin-4-yl]piperazinyl}-N-(4-indolin-4-yloxyprιenyl) carboxamide
Figure imgf000010_0005
{4-[6-(2-methoxyethoxy)-7-(2-morpholin-4-ylethoxy)quinazolin-4-yl]piperazinyl}- N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000011_0001
{4-[7-(2-methoxyethoxy)-6-(2-piperidylethoxy)quinazolin-4-yl]piperazinyl}- N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000011_0002
N-(4-cyanophenyl){4-[7-(2-methoxyethoxy)-6-(2-piperidylethoxy)quinazolin-4-yl] piperazinyljcarboxam ide
CN
Figure imgf000011_0003
{4-[6-(2-methoxyethoxy)-7-(2-pyrroIidinylethoxy)quinazolin-4-yl]piperazinyl }-N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000012_0001
N-(4-cyanophenyI){4-[6-(2-methoxyethoxy)-7-(2-pyrrolidinylethoxy) quinazolin-4-yl]piperazinyl}carboxamide
Figure imgf000012_0002
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The compounds may be prepared using methods and procedures as generally described in WO 98/14431 published September 12, 1998, which is incorporated herein by reference. Starting materials may be made or obtained as described therein as well. Leaving groups such as halogen, lower alkoxy, lower alkylthio, lower alkylenesulfonyloxy, arylsulfonyloxy, etc, may be utilized when necessary except for the reaction point, followed by deprotection. Suitable amino protective groups are, for example, those described in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981), etc., such as ethoxycarbonyl, t-butoxycarbonyl, acetyl and benzyl. The protective groups can be introduced and eliminated according to conventional methods used in organic synthetic chemistry [e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981)]. In such processes, if the defined groups change under the conditions of the working method or are not appropriate for carrying out the method, the desired compound can be obtained by using the methods for introducing and eliminating protective groups which are conventionally used in organic synthetic chemistry [e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons Inc. (1981)], etc. Conversion of functional groups contained in the substituents can be carried out by known methods [e.g., R. C. Larock, Comprehensive Organic Transformations (1989)] in addition to the above-described processes, and some of the active compounds of formula I may be utilized as intermediates for further synthesizing novel derivatives according to formula I.
The intermediates and the desired compounds in the processes described above can be isolated and purified by purification methods conventionally used in organic synthetic chemistry, for example, neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography. The intermediates may be subjected to the subsequent reaction without purification.
There may be tautomers for some formula I, and the present invention covers all possible isomers including tautomers and mixtures thereof. Where chiral carbons lend themselves to two different enantiomers, both enantiomers are contemplated as well as procedures for separating the two enantiomers.
In the case where a salt of a compound of formula I is desired and the compound is produced in the form of the desired salt, it can be subjected to purification as such. In the case where a compound of formula I is produced in the free state and its salt is desired, the compound of formula I is dissolved or suspended in a suitable organic solvent, followed by addition of an acid or a base to form a salt.
The following non-limiting reaction Schemes I and II illustrate preferred embodiments of the invention with respect to making compounds according to the invention. Scheme I
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000014_0003
M eO MeO .
This synthesis of 6,7-bis(2-methoxyethoxy)-4-piperaziny xlquinazoόline compound, provides an intermediate that can be utilized in the synthesis of various compounds (the scheme can be adapted to produce bicyclic position isomers) as described above for formula I. The ethyl 3,4-dihydroxybenzoate is alkylated with 2-bromoethylmethyl ether, followed by nitration with potassium nitrate at room temperature. The nitro functionality is reduced under hydrogenation condition, followed by cyclization with formamide at elevated temperature, preferably in the range 100 to 200°C to afford quinazolinone. The synthesis of 4-Cl-quinazoline is effected by treating 4-quinazolinone with halogenatmg reagents such as thionyl chloride, oxalyl chloride or phosphorous oxychloride in presence of solvent such as toluene, or carbon tetrachloride. The key intermediate is obtained by treating 4-C1- quinazoline with piperazine in an appropriate solvent, such as isopropanol, acetonitrile, or THF at room or reflux temperature for l-6h in presence of base triethylamine or pyridine.
Scheme 2 (below) provides the synthesis of various substituted urea intermediates from the intermediate obtained above in Scheme 1, or by other procedures. The treatment of intermediate formed in Scheme 1 with various isocyanates afforded the final urea compounds. In cases where the isocyanates are not commercially available, the piperazine intermediate may be treated with phosgene to give a carbamoyl chloride intermediate followed by reaction with various substituted anilines. The piperazine intermediate can also be treated with p-nitrophenyl chloroformate to afford a nitrophenyl carbamate intermediate that can be treated with various anilines to afford the desired ureas. If the urea compound has a terminal NH2 group (or one or more of the hydrogen atoms on this amino group is replaced by a displaceable substituent), then this compound may be utilized an intermediate compound with which to produce a urea compound terminated with a -NH-phenyl-R1 groups. Alternatively, if a different R1 group is desired on the phenyl group, a replaceable para position leaving group phenyl substituent may be displaced after coupling to provide the particular R1 substituent as described for formula I, above.
Scheme II
Figure imgf000016_0001
Such procedures for producing the claimed compounds are merely an illustration of a preferred aspect of the invention. Other procedures and adaptations will be apparent to one of ordinary skill in the art upon views these reaction schemes and the structures of the compounds according to the invention. Such procedures are deemed to be within the scope of the present invention.
Also, the compounds of formula I and pharmaceutically acceptable salts thereof may exist in the form of adducts with water (hydrates) or various solvents, which are also within the scope of the present invention.
The following non-limiting examples are provided to better illustrate the present invention. Example 1
The intermediate 6,7-bis(2-methoxyethoxy)-4-piperazinyquinazoline
Figure imgf000017_0001
was prepared using the procedures as generally described in reaction Schemes I as follows:
Step A: To the acetone solution (lOmL) of ethyl 3,4-dihydroxybenzoate (0.910g, 5mmol), K2CO3 (1.52g, llmmol), nBu4NI (20mg) was added 2-bromoethylmethyl ether (1.17mL, 12.5mmol). The mixture was stirred overnight at 100°C under argon. After cooling, to this added ether and the precipitate was filtered, the filtrate was evaporated to afford the desired product as white solid (0.850g, 60%).
Step B: To the acetic acid (4mL) solution of ethyl-3,4-bis(2-methoxyethoxy)benzoate (0.710g, 2.4mmol) at -10°C was slowly added nitric acid ( 0.350mL). After stirring at this temperature for lh, added KNO3 (0.240g, 2.4mmol) and H2SO4 (0.180mL) followed by stirring at room temperature overnight. The reaction was poured in ice and extracted with EtOAc, washed with brine, dried, filtered and evaporated to give brown oil (0.800g, quantitative). MS(ES) 344 (M+H)+
Step C: To the EtOH (lOmL) solution of nitro material from Step B (0.686g, 2mmol) added PtO2 (40mg, 0.16mmol) and then the mixture was shaken on Parr hydrogenation apparatus at 45psi of H2 for overnight. Filtration of the catalyst through celite and evaporation of the solvent under vacuum gave the desired amino ester (0.600g). MS(ES) 314 (M+H) Step D: The amino product (lg, 3.21mmol) from Step C was dissolved in formamide (4mL) to this added ammonium formate (0.298g, 4.71mmol) and the reaction mixture was heated at 150°C for 4h. After cooling to room temperature, the solution was diluted with water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, filtered and evaporated to give beige-colored solid (0.600g, 62%).
Step E: A mixture of 6,7-bis(2-methoxyethoxy)-4-quinazolinone (0.969g, 3.3mmol) and POCl3 (4.5mL) was heated to reflux under argon for 6h. After cooling to 0°C, added dropwise cone. NH4OH, a solid precipitated which was collected by filtration. The solid collected was washed with water and dried under high vacuum to afford desired 4- chloroquinazoline.
Step F: To the isopropanol solution (5mL) of 6,7-bis(2-methoxyethoxy)-4-Cl-quinazoline (0.156g, 0.5mmol, from Step E) added piperazine (0.300g, 3.5mmol) and the reaction mixture was refluxed for 3h. The solvent was evaporated and the residue dissolved in EtOAc and washed with brine, dried, filtered and evaporated to give desired key intermediate 6,7-bis(2-methoxyethoxy)-4-piperazinyquinazoline as a white solid (0.150g). MS(ES) 363(M+H)
Example 2
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4- cyanophenyl)piperazinyl carboxamide was prepared using the intermediate obtained in Example 1 and the procedures as generally described in reaction Scheme II as follows:
Figure imgf000019_0001
To DMF solution (ImL) of 6,7-bis(2-methoxyethoxy)-4-piperazinyquinazoline from Step F Example 1 (O.lOOg, 0.27mmol) was added DMF solution (ImL) of 4- cyanophenylisocyanate (75mg, 0.45mmol) and the reaction was stirred at room temperature overnight. The solvent was evaporated and residue purified by RP-HPLC to afford desired product {4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4- cyanophenyl)piperazinyl carboxamide as a white solid (0.100, 73%). MS(ES) 507(M+H)+
Examples 3
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4- phenoxyphenyl)carboxamide was prepared using the following procedure:
Figure imgf000019_0002
To the acetonitrile solution (ImL) of triphosgene (26.4mg, 0.09mmol) at -5°C added a solution of 4-phenoxyaniline (91.6mg, 0.26mmol, prepared as described in Example 3, Step B) and Et3N (73.2DL) in acetonitrile (ImL) over a period of 5min. To this was added a acetonitrile solution (ImL) of 6,7-bis(2-methoxyethoxy)-4-piperazinyquinazoline (125mg, 0.09mmol, Example 1, Step F) and Et3N (73.2DL). The reaction slowly warmed up to room temperature and stirred for 3h. The solvent was evaporated and the residue purified by RP- HPLC (reverse-phase high performance liquid chromatography) to afford desired {4-[6,7- bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl} -N-(4-phenoxyphenyl)carboxamide as a flaky shiny white solid (132mg, 75%). MS(ES) 574 (M+H)
The starting material 4-phenoxyaniline was synthesized as follows:
TFA.H2N- -o-
% W /
Step A: To the anhydrous DMSO solution (7mL) of phenol (0.44g, 4.7mmol) added NaH (0.24g, 6.05mmol) and stirred for 45min at room temperature. To this added l-fluoro-4- nitrobenzene(0.66g, 4.65mmol) and this was heated at 90°C for overnight. After cooling diluted with EtOAc and washed with brine, dried, filtered, evaporated to afford crude residue. This was purified by silica gel cliromatography (10%EtOAc/hexane) to give desired product as bright yellow oil (0.91 g, 91%). MS(ES) 216 (M+H)
Step B: The nitro compound from Step A (0.885g, 4.12mmol) was dissolved in
EtOH/EtOAc (lOmL, 1:1), to this added 10%Pd/C (O.lOOg) and TFA (0.317mL, 4.12mmol). The reaction mixture was stirred under latm H2 for overnight, filtered through celite. The filtrate was concentrated in vacuo to afford 4-phenoxyaniline as a pink solid (1.15g, 93.5%). MS(ES) 186 (M+H)+
Examples 4 tert-butyl-4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4- yl]piperazinylcarboxylate:
Figure imgf000021_0001
was prepared using the following procedure:
Step A: To the DMF solution (12mL) of Ethyl-3-hydroxy-4-fluorobenzoate (0.80g, 4.35mmol) added K2CO3 (2.10g, 15.22mmol) followed by 2-bromoethyl methylether
(0.45mL, 4.76mmol). The reaction mixture was heated at 70°C for overnight, after cooling added water and extracted the product with EtOAc. The EtOAc layer was dried, filtered and evaporated to afford desired product as pale yellow oil (1.04g, 90%).
Step B: To a DMF solution (lOmL) of 2-piperidineethanol (2.86mL, 21.6mmol) added NaH(0.83g, 20.9mmol) at 0°C and the mixture was stirred for lh. To this added DMF solution (3mL) of ester (0.725g, 3.15mmol, from Step A, Example 4) and heated the reaction at 90°C overnight. The solvent was evaporated and the residue purified by RP-HPLC to afford the desired ethyl 3-(2-methoxyethoxy)-4-(2-piperidylethoxy)benzoate as a off-white solid. MS(ES) 352(M+H)
Step C: To the acetic acid (3mL) solution of ethyl 3-(2-methoxyethoxy)-4- (2- piperidylethoxy)benzoate (0.197g, 0.56mrnoι) at -10°C was slowly added nitric acid ( 0.200mL). After stirring at this temperature for lh, added KNO3 (0.056g, 0.56mmol) and H2SO4 (0.200mL) slowly warmed up to room temperature and stirred for lh. The reaction was poured in ice, basified with NH4OH, and extracted with EtOAc. The EtOAc layer was separated, dried, filtered and evaporated to give white solid (0.200g, 95%). MS(ES) 397 (M+H)+ Step D: To the EtOH (lOmL) solution of nitro material from Step C (0.200g, 0.5mmol) added 10%Pd/C and then the mixture was stirred under latm of H2 for overnight. Filtration of the catalyst through celite and evaporation of the solvent under vacuum gave the desired amino ester (0.162g). MS(ES) 367 (M+H)
Step E: The amino product (0.160g, 0.437mmol) from Step D was dissolved in formamide (0.278mL, 7mmol)) to this added ammonium formate (0.256g, 4.36mmol) and the reaction mixture was heated at 135°C for 4h. After cooling to room temperature, the solution was diluted with water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, filtered and evaporated to give off-white solid (0.198g, 96%). MS(ES) 370 (M+Na).
Step F: To 4-quinazolinone (0.195g, 0.423mmol, From Step E) added SOCl2 (3mL), DMF (0.200mL) and the mixture was heated at 90°C for lh. After cooling evaporated the solvent and azetroped several times with toluene to afford the desired 4-Cl-quinazoline as tan crystalline solid (0.197g). ES(MS) 366 (M+H, with 1C1).
Step G: To the isopropanol solution (8mL) of the material from Step F (0.190g, 0.423mmol) added Boc-piperazine (0.197g, 1.06mmol) followed by Et3N (0.288mL, 2.1 lmmol). The reaction mixture was heated to reflux overnight. The solvent was evaporated and the residue purified by RP-HPLC to afford desired product tert-butyl-4-[6- (2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl]piperazinylcarboxylate (0.173g, 62%). MS(ES) 516 (M+H).
Example 5 N-(4-cyanophenyl)piperazinyl {4-[6-(2-methoxyethoxy)-7-(2- piperidylethoxy)quinazolin-4-yl]piperazinyl} carboxamide was prepared using the intermediate obtained in Example 2 and the procedures as generally described in reaction Scheme II as follows:
Figure imgf000023_0001
To tert-butyl-4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4- yljpiperazinylcarboxylate (from Example 4, Step G, 0.055g, 0.107mmol) added 4N HCl/dioxane (ImL) and reaction was stirred at rom temperature for lh. The solvent was evaporated to afford deboc material, (t e. material with the Boc protecting group removed), to this added DMF (ImL), Et3N (0.200mmol) followed by DMF solution (ImL) of 4- cyanophenylisocyanate (20mg, 0.133mmol) and the reaction was stirred at RT overnight. The solvent was evaporated and residue purified by RP-HPLC to afford desired product N- (4-cyanophenyl)piperazinyl{4-[6-(2-methoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4- yljpiperazinyl} carboxamide as a white solid (0.053g, 73%). MS(ES) 560(M+H)+
The pharmacological activities of the compounds of the present invention are obtained by following the test example procedures as follows, for example.
Biological Test Assay Type 1
Inhibitory effect on compounds on Autophosphorylation of Platelet Derived Growth Factor β-PDGF receptor
(1) HR5 Phosphorylation Assay
The HR5 cell line is a cell line of CHO cells engineered to overexpress human ?-PDGFR, which cell line is available from the ATCC. The expression level of /?-PDGFR in HR5 cells is around 5 xlO4 receptor per cell. For the phosphorylation assay according to the invention, HR5 cells were grown to confluency in 96-well microtiter plates under standard tissue culture conditions, followed by serum-starvation for 16 hours. Quiescent cells were incubated at 37°C without or with increasing concentrations of the test compound (0.01-30 μM) for 30 minutes followed by the addition of 8 nM PDGF BB for 10 minutes. Cells were lysed in 100 mM Tris, ρH7.5, 750 mM NaCl, 0.5% Triton X-100, 10 mM sodium pyrophosphate, 50 mM NaF, 10 ug/ml aprotinin, 10 ug/ml leupeptin, lmM phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, and the lysate was cleared by centrifugation at 15,000 x g for 5 minutes. Clarified lysates were transferred into a second microtiter plate in which the wells were previously coated with 500 ng/well of 1B5B11 anti- Ϊ-PDGFR mAb, and then incubated for two hours at room temperature. After washing three times with binding buffer (0.3% gelatin, 25mM Hepes pH 7.5, lOOmM NaCl, 0.01% Tween-20), 250 ng/ml of rabbit polyclonal anti-phosphotyrosine antibody (Transduction Laboratory) was added and plates were mcubated at 37°C for 60 minutes. Subsequently, each well was washed three times with binding buffer and incubated with 1 ug/ml of horse radish peroxidase-conjugated anti-rabbit antibody (Boeliringer Mannheim) at 37°C for 60 minutes. Wells were washed prior to adding ABTS (Sigma), and the rate of substrate formation was monitored at 650nm. The assay results are reported as IC50 (expressed as the concentration of a compound according to the invention that inhibits the PDGF receptor phosphorylation by 50%) as compared to control cells that are not exposed to a compound according to the invention.
Examples of such IC50 test results in the HR5 assay for compounds according to the invention are set forth below in Table 1.
(2) MG63 Phosphorylation Assay
The MG63 cell line is a human osteosarcoma tumor cell line available from the
ATCC. This assay is for measuring endogenous 7-PDGFR phosphorylation in MG63 cells. The assay conditions are the same as those described for HR5 cell, except that PDGF-BB stimulation is provided in the presence or absence of 45% human plasma. The MG63 assay results are reported as an IC50 (expressed as the concentration of a compound according to the invention that inhibits the PDGF receptor phosphorylation by 50%) as compared to control cells that are not exposed to a compound according to the invention. Examples of such IC50 test results in the MG63 assay for compounds according to the invention are set forth below in Table 1.
The assay results for Compound Examples 2 and 3 are set forth in Table 1 below.
Table 1
Figure imgf000025_0001
Biological Test Assay Type 2
Growth inhibition against smooth muscle cells
Vascular smooth muscle cells are isolated from a pig aorta by explanation and used for the test. The cells are put into wells of a 96-well plate (8000 cells/well) and cultured in
Dulbeccois modified Eagle's medium (DMEM; Nissui Pharmaceutical Co., Ltd.) containing 10% fetal bovine serum (FBS; Hyclone) for 4 days. Then, the cells are further cultured in
DMEM containing 0.1 % FBS for 3 days, and are synchronized at the cell growth stationary phase.
To each well is added DMEM containing 0.1% FBS and a test sample at a varied concentration, and the cell growth is brought about by PDGF-BB (SIGMA, final concentration: 20 ng/ml). After culturing for 3 days, the cell growth is measured using a cell growth assay kit (Boehringer Mannheim) according to the XTT method [J. Immunol.
Methods, 142, 257-265 (1991)], and the cell growth score is calculated by the following equation.
Cell growth score = 100 x {1-(M-PO)/(P100-PO)} wherein P100 = absorbance by XTT reagent when stimulated by PDGF-BB; PO = absorbance by XTT reagent when not stimulated by PDGF-BB, and M = absorbance by XTT reagent after addition of a sample when stimulated by PDGF-BB.
The test result is expressed as the concentration of a test compound which inhibits the cell growth by 50% (IC50).
Biological Test Assay Type 3
Inhibitory effect on hypertrophy of vascular intima
Male SD rats (weight: 375-445 g, Charles River, golden standard) are anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and then the neck of each animal is incised by the median incision, followed by retrograde insertion of a balloon catheter (2F, Edwards
Laboratories) into the left external carotid. After the above treatment is repeated seven times, the catheter is pulled out, the left external carotid is ligated, and the wound is sutured.
A test compound is suspended in a 0.5% solution of Tween 80 in an aqueous solution of sodium chloride to a concentration of 20 mg/ml in the case of intraperitoneal administration and in a 0.5% solution of methyl cellulose 400 to a concentration of 6 mg/ml in the case of oral administration. The suspension is administered once a day in the case of intraperitoneal administration and once or twice a day in the case of oral administration for a period of 15 days starting on the day before the balloon injury. On the 14th day after the balloon injury, the animal is killed and its left carotid is extirpated. The tissues are fixed with formalin, wrapped in paraffin and sliced, followed by Elastica Wangeeson staining. The area of the cross section of the vascular tissues (intima and media) is measured with an image analyzer
(Luzex F, NIRECO) and the intima/media area ratio (I/M) is regarded as the degree of hypertrophy of the vascular intima. From the results obtained, it is apparent when the hypertrophy of vascular intima is significantly inhibited by administration of the compounds of the present invention.
Biological Test Assay Type 4 Evaluation by the use of a rat adjuvant arthritis model
Dead cells of Mycobacterium bacterium (Difco Laboratories Inc.) are disrupted in agate mortar and suspended in liquid paraffin to the final concentration of 6.6 mg/ml, followed by sterilization with high pressure steam. Then, 100 ml of the suspension is subcutaneously injected into the right hind foot pad of each animal of groups of female 8-weeks-old Lewis rats (Charles River Japan) (6 animals/group) to induce adjuvant arthritis. A test compound i suspended in a 0.5 % solution of methyl cellulose to the final concentration of 3 mg/ml, and from just before the induction of arthritis, the suspension is orally administered in an amount of 100 ml/100 g of the body weight once a day, 5 days a week. To a control group is administered a 0.5% solution of methyl cellulose. A normal group is given no adjuvant treatment or test compound administration. The administration of the test compound is continued till the 18th day after the adjuvant treatment. On the 17th day, the number of leukocytes in peripheral blood are counted, and on the 18th day, all the blood is collected, followed by dissection.
The change in body weight with the passage of time, the change of edema in hind foot with the passage of time, the weight of spleen and thymus, the number of leukocytes in peripheral blood, the hydroxyproline content of urine, the glucosaminoglycan content of urine, the SH concentration in serum, the concentration of nitrogen monoxide in serum and the concentration of mucoprotein in serum are measured and evaluated. The volume of each of both hind feet are measured using a rat's hind foot edema measurement device (TK-101, Unicom). The number of leukocytes in peripheral blood are counted using an automatic multichannel blood cell counter (Sysmex K-2000, Toa Iyo Denshi Co., Ltd.). The hydroxyproline content of urine is measured according to the method described in Ikeda, et al., Annual Report of Tokyo Metropolitan Research Laboratories P. H., , 36, 277 (1985), and the glucosaminoglycan content is measured according to the method described in Moriyama, et al., Hinyo Kiyo, 40, 565 (1994) and Klompmakers, et al., Analytical Biochemistry, 153, 80 (1986). The SH concentration in serum is measured according to the method described in Miesel, et al, inflammation, 17, 595 (1993), and the concentration of nitrogen monoxide is measured according to the method ofTracey, et al., Journal of Pharmacology & Experimental Therapeutics, 272, 1011 (1995). The concentration of mucoprotein is measured using Aspro GP Kit (Otsuka Pharmaceutical Co., Ltd.). The percentage inhibition for each indication is calculated according to the following equation.
% Inhibition = {(Control group - Compound-administered group)/(Control group - Normal group)} x 100.
From the results obtain from such assays, it is apparent when the compound according to the invention inhibits the occurrence of adjuvant arthritis.
Biological Test Assay Type 5
Activity on a mesangial proliferative glomerulonephritis model
Anti-rat Thy-1.1 monoclonal antibody OX-7 (Sedaren) is administered to male Wister-Kyoto rats (Charles River Japan, 160 g, 6 animals/group) in an amount of 1.0 mg/kg by intravenous administration through the tail vein. A test compound is suspended in a 0.5% solution of methylcellulose and the resulting suspension is administered to each of the rats twice a day for a period of 7 days starting on the day before the administration of OX-7. On the 7th day after the OX-7 administration, when mesangial cell growth and extracellular matrix hypertrophy become prominent, the left kidney of each rat is extirpated, fixed with 20% buffered formalin for 6 hours and wrapped in paraffin, followed by slicing. The obtained pieces are subjected to immune tissue staining using antibody PC 10 (DAKO) against an intranuclear antigen of proliferative cells. After comparative staining with Methyl Green staining solution using diaminobenzidine as a color developer, the paraffin pieces are enclosed. Half of the glomeruli in a kidney piece are observed and the number of the cells in one glomerulus which are positive to the intranuclear antigen of proliferative cells are calculated. The test for the significance of difference is carried out by the Wilcoxon test.
From such results, it is apparent when the compounds according to the present invention show alleviating activity on mesangial proliferative glomerulonephritis. The compounds of formula (I) and pharmaceutically acceptable salts thereof can be administered as such, but it is usually preferred to administer them in the form of pharmaceutical compositions, which are used for animals and human beings. It is preferred to employ the administration route which is the most effective for the treatment. For example, administration is made orally or non-orally by intrarectal, intraoral, subcutaneous, intramuscular or intravenous administration.
Examples of the forms for administration are capsules, tablets, granules, powders, syrups, emulsions, suppositories and injections.
Liquid compositions such as emulsions and syrups which are appropriate for oral administration can be prepared using water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as benzoates, flavors such as strawberry flavor and peppermint, etc.
Capsules, tablets, powders and granules can be prepared using excipients such as lactose, glucose, sucrose and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, etc.
Compositions suitable for non-oral administration preferably comprise a sterilized aqueous preparation containing an active compound which is isotonic to the recipient's blood. For example, injections are prepared using a carrier which comprises a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
Compositions for topical application are prepared by dissolving or suspending an active compound in one or more kinds of solvents such as mineral oil, petroleum and polyhydric alcohol, or other bases used for topical drugs. Compositions for intestinal administration are prepared using ordinary carriers such as cacao fat, hydrogenated fat and hydrogenated fat carboxylic acid, and are provided as suppositories.
The compositions for non-oral administration may additionally be formulated to contain one or more kinds of additives selected from glycols, oils, flavors, preservatives
(including antioxidants), excipients, disintegrating agents, lubricants, binders, surfactants and plasticizers which are used for the preparation of compositions for oral administration. The effective dose and the administration schedule for each of the compounds of formula (I) or a pharmaceutically acceptable salt thereof will vary depending on the administration route, the patient's age and body weight, and the type or degree of the diseases to be treated. However, it is generally appropriate to administer a compound of formula (I) or a pharmaceutically acceptable salt thereof in a dose of 0.01-1000 mg/adult/day, preferably 5-500 mg/adult/day, in one to several parts.
All the compounds of the present invention can be immediately applied to the treatment of kinase-dependent diseases of mammals as kinase inhibitors, specifically, those relating to tyrosine kinase. Specifically preferred are the compounds which have IC50 within the range of 10 nM-10 μM. Even more preferred are compounds which have IC50 within the range of 10 μM to -1 μM. Most preferred are compounds which have an IC50 value which is smaller than 1 μM. Specific compounds of the present invention which have an activity to specifically inhibit one of the three types of protein kinase (for example, kinase which phosphorylates tyrosine, kinase which phosphorylates tyrosine and threonine, and kinase which phosphorylates threonine) can be selected. Tyrosine kinase-dependent diseases include hyperproliferative malfunction which is caused or maintained by abnormal tyrosine kinase activity. Examples thereof include psoriasis, pulmonary fibrosis, glomerulonephritis, cancer, atherosclerosis and anti-angiopoiesis (for example, tumor growth and diabetic retinopathy). Current knowledge of the relationship between other classes of kinase and specific diseases is insufficient. However, compounds having specific PTK-inhibiting activity have a useful treatment effect. Other classes of kinase have also been recognized in the same manner. Quercetin, genistein and staurosporin, which are all PTK-inhibitors, inhibit many kinds of protein kinase in addition to tyrosine kinase. However, as a result of their lack of the specificity, their cytotoxicity is high. Therefore, a PTK-inhibitor (or an inhibitor of other classes of kinase) which is apt to bring about undesirable side effects because of the lack of selectivity can be identified by the use of an ordinary test to measure cytotoxicity.
The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Although the present invention has been described in some detail by way of illustration for purposes of clarity of understanding, it will be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. All the patents, journal articles and other documents discussed or cited above are herein incorporated by reference in their entirety.

Claims

WHAT IS CLAIMED IS:
A nitrogen-containing heterocyclic compound of the formula:
Figure imgf000032_0001
wherein m and n are each independently from 2 to 8,
X is O or S; and
Ris a member selected from the group consisting of:
-CN, -C-(CH3)3, -C-(CF3)2-OH, -N(-CM alkyl, -C 6 alkyl), -OCH(CH3)2,
Figure imgf000032_0002
R1 and R2 are each independently a member selected from the group consisting of -OH, -O-CH3,
Figure imgf000033_0001
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
2. The compound of claim 1, having formula 1(a) as follows:
Figure imgf000033_0002
wherein
R is defined as in claim 1,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof. The compound of claim 1, having formula 1(b) as follows:
Figure imgf000034_0001
wherein
R, R2 and m are each independently defined as described in claim 1 above,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
4. The compound of claim 3, wherein m is 2 or 3.
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
5. The compound of claim 1, having formula 1(c) as follows:
Figure imgf000034_0002
wherein
R, R1 and n are each independently defined as described above in claim 1, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
6. The compound of claim 5, wherein n is 2 or 3,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
A compound according to claim 1, selected from the group consisting of:
Figure imgf000036_0001
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-naphthyloxyphenyl) carboxam ide
Figure imgf000036_0002
{4-[6,7-bis(2-m ethoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-(5-isoquinolyloxy)phenyl) carboxam ide
Figure imgf000036_0003
{4-[6,7-bis(2-m ethoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-indol-4-yloxyphenyl) carboxam ide
Figure imgf000036_0004
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-[4-(3-chloro-4-methylphenoxy) phenyl]carboxamide
Figure imgf000037_0001
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-[4-(4-bromophenoxy)phenyl] carboxamide
Figure imgf000037_0002
{4-[6,7-bis(2-methoxyethoxy x)quinazoliόn-4-yl]piperazinyl}-N-(4-cyclopropylphenyl) carboxamide
Figure imgf000037_0003
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-(5-1 ,2,3,4-tetrahydroisoquinolyloxy) phenyl)carboxamide
Figure imgf000037_0004
{4-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-indolin-4-yloxyphenyl) carboxamide
Figure imgf000037_0005
{4-[6-(2-m ethoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl]piperaziπyl}- N-(4-phenoxyphenyl)carboxam ide
Figure imgf000038_0001
N-(4-cyanophenyl){4-[6-(2-m ethoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl] piperazinyljcarboxam ide
Figure imgf000038_0002
{4-[6-(2-m ethoxyethoxy)-7-(2-piperidylethoxy)quinazolin-4-yl]piperazinyl}- N-[4-(m ethylethoxy)phenyl]carboxam ide
Figure imgf000038_0003
N-(4-cyanophenyl){4-[6-(2-m ethoxyethoxy)-7-(2-m orpholin-4-ylethoxy)quinazolin-4-yl] piperazinyljcarboxam ide
Figure imgf000038_0004
{4-[6-(2-methoxyethoxy)-7-(2-morpholin-4-ylethoxy)quinazolin-4-yl]piperazinylJ- N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000039_0001
{4-[7-(2-methoxyethoxy)-6-(2-piperidylethoxy)quinazolin-4-yl]piperazinylJ- N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000039_0002
N-(4-cyanophenyl){4-[7-(2-methoxyethoxy)-6-(2-piperidylethoxy)quinazolin-4-yl] piperazinyljcarboxam ide
Figure imgf000039_0003
{4-[6-(2-methoxyethoxy)-7-(2-pyrrolidinylethoxy)quinazolin-4-yl]piperazinyl }-N-[4-(methylethoxy)phenyl]carboxamide
Figure imgf000040_0001
N-(4-cyanophenyl){4-[6-(2-methoxyethoxy)-7-(2-pyrrolidinylethoxy)quinazolin-4-yl]piperazinyl}carboxamide
Figure imgf000040_0002
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
8. A pharmaceutical composition comprising an effective amount of a nitrogen-containing heterocyclic compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
9. A method of inhibiting phosphorylation of PDGF receptor in a patient comprising administering a composition according to claim 8 to the patient.
10. A method for inhibiting abnormal cell growth and cell wandering in a patient and thereby preventing or treating a cell-proliferative disease, comprising the step of administering a composition according to claim 8 to the patient.
11. A method according to claim 10, wherein said cell-proliferative disease is selected from the group consisting of arteriosclerosis, vascular re-obstruction, restenosis, cancer and glomerulosclerosis.
PCT/US2001/041749 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds WO2002016360A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/344,907 US20040259881A1 (en) 2001-02-02 2001-08-17 Nitrogenous heterocyclic compounds
AU2001293207A AU2001293207A1 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds
EP01973652A EP1309567A2 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26612000P 2000-08-18 2000-08-18
US60/266,120 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002016360A2 true WO2002016360A2 (en) 2002-02-28
WO2002016360A3 WO2002016360A3 (en) 2002-06-13

Family

ID=23013247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041749 WO2002016360A2 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Country Status (3)

Country Link
EP (1) EP1309567A2 (en)
AU (1) AU2001293207A1 (en)
WO (1) WO2002016360A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951937B2 (en) * 2000-11-01 2005-10-04 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US6956039B2 (en) 2000-08-18 2005-10-18 Millennium Pharmaceuticals, Inc. Nitrogenous heterocylic compounds
US6960580B2 (en) 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
US6982266B2 (en) 2000-08-18 2006-01-03 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
EP1650196A1 (en) * 2003-07-30 2006-04-26 Ube Industries, Ltd. Process for producing 6,7-bis(2-methoxyethoxy)-quinazolin-4-one
WO2006135646A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis
US7329655B2 (en) 2000-08-18 2008-02-12 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
EP1937252A2 (en) * 2005-09-19 2008-07-02 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CN108358798A (en) * 2018-02-12 2018-08-03 黑龙江鑫创生物科技开发有限公司 A kind of method of micro passage reaction synthesis Tarceva intermediate
WO2021017996A1 (en) * 2019-07-26 2021-02-04 暨南大学 Phenylpiperazine quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882717A1 (en) * 1996-10-01 1998-12-09 Kyowa Hakko Kogyo Kabushiki Kaisha Nitrogenous heterocyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882717A1 (en) * 1996-10-01 1998-12-09 Kyowa Hakko Kogyo Kabushiki Kaisha Nitrogenous heterocyclic compounds

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329655B2 (en) 2000-08-18 2008-02-12 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
US6956039B2 (en) 2000-08-18 2005-10-18 Millennium Pharmaceuticals, Inc. Nitrogenous heterocylic compounds
US8022071B2 (en) 2000-08-18 2011-09-20 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
US6982266B2 (en) 2000-08-18 2006-01-03 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US7560461B2 (en) 2000-08-18 2009-07-14 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US8324205B2 (en) 2000-08-18 2012-12-04 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US6951937B2 (en) * 2000-11-01 2005-10-04 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US8536184B2 (en) 2000-11-01 2013-09-17 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US7709640B2 (en) 2000-11-01 2010-05-04 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
USRE43098E1 (en) 2000-11-01 2012-01-10 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US6960580B2 (en) 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
EP1650196A4 (en) * 2003-07-30 2007-02-28 Ube Industries Process for producing 6,7-bis(2-methoxyethoxy)-quinazolin-4-one
EP1650196A1 (en) * 2003-07-30 2006-04-26 Ube Industries, Ltd. Process for producing 6,7-bis(2-methoxyethoxy)-quinazolin-4-one
WO2006135646A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
EP1937252A4 (en) * 2005-09-19 2010-07-28 Neuronascent Inc Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US8039462B2 (en) 2005-09-19 2011-10-18 Neuronascent, Inc. Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
KR101132378B1 (en) * 2005-09-19 2012-04-03 뉴로내슨트, 아이엔씨. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
JP2009508876A (en) * 2005-09-19 2009-03-05 ニューロナセント インコーポレイテッド Methods and compositions for stimulating neurogenesis and for inhibiting neuronal degeneration
AU2006292256B2 (en) * 2005-09-19 2013-05-02 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
EP1937252A2 (en) * 2005-09-19 2008-07-02 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US8999972B2 (en) 2005-09-19 2015-04-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US9539261B2 (en) 2005-09-19 2017-01-10 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CN108358798A (en) * 2018-02-12 2018-08-03 黑龙江鑫创生物科技开发有限公司 A kind of method of micro passage reaction synthesis Tarceva intermediate
WO2021017996A1 (en) * 2019-07-26 2021-02-04 暨南大学 Phenylpiperazine quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof

Also Published As

Publication number Publication date
WO2002016360A3 (en) 2002-06-13
AU2001293207A1 (en) 2002-03-04
EP1309567A2 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
EP1315715B1 (en) Quinazoline derivatives as kinase inhibitors
EP1382604B1 (en) Quinoline derivative having azolyl group and quinazoline derivative
US20060063770A1 (en) Nitrogenous heterocyclic compounds
RU2396261C2 (en) Quinazoline derivatives effective as vaniloid antagonists
EP1490362A2 (en) (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2002016360A2 (en) Nitrogenous heterocyclic compounds
US8022071B2 (en) Nitrogenous heterocyclic compounds
US20040259881A1 (en) Nitrogenous heterocyclic compounds
AU2001285449B8 (en) Quinazoline derivatives as kinase inhibitors
AU2001285449A1 (en) Quinazoline derivatives as kinase inhibitors
AU778961B2 (en) Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001973652

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001973652

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10344907

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001973652

Country of ref document: EP